Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LOYYU
ADC Name	MMAE-9F7-F11 ADC
Synonyms	9F7-F11 MMAE Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	3.4-4.3
	3D MOL	2D MOL
Antibody Name	Anti-HER3 mAb 9F7-F11		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-3 (ERBB3)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 1.98	ng/mL	BxPC-3 cells	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 1.98 ng/mL±0.74 ng/mL	Positive HER3 expression (HER3+++/++)
Method Description	Cells were plated in 96-well flat-bottom plates the day before starvation in 1% FCS for 24hr. HER3-ADC at different dilutions was then added for 5 days, with 50ng/ml NRG1. In the absence of NRG1 stimulation, cells were maintained in 10% FCS and treated with HER3-ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

References

Ref 1	An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer. 2019 Oct 1;145(7):1838-1851. doi: 10.1002/ijc.32273. Epub 2019 Apr 1.